Clinical trials: Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Middle East Respiratory Syndrome Coronavirus
Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults
Background: Middle East Respiratory Syndrome (MERS) is a newly discovered contagious and sometimes fatal respiratory virus. People often get MERS through close contact with an infected person.
- Trial name
- NCT02788188
- Testing
- SAB-301, Normal (9%) Saline
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by…
- Trial name
- NCT04588428
- Testing
- INO-4700, CELLECTRA™ 2000
- Where
- 6 sites in Jordan, Kenya and 1 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
MERS (Middle East Respiratory Syndrome)
Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a potentially fatal disease with a reported lethality of up to 40% that is under tight epidemiologic control by the World Health Organization (WHO) and currently…
- Trial name
- NCT03615911
- Testing
- vaccine candidate MVA-MERS-S
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Marylyn Addo